Relay Therapeutics, Inc.
RLAY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $900 | $593 | $443 | $689 |
| - Cash | $92 | $114 | $94 | $124 |
| + Debt | $33 | $34 | $47 | $49 |
| Enterprise Value | $842 | $513 | $397 | $614 |
| Revenue | – | $1 | $8 | $0 |
| % Growth | – | -91.2% | – | – |
| Gross Profit | -$1 | $1 | $8 | $0 |
| % Margin | – | 100% | 100% | – |
| EBITDA | -$73 | -$76 | -$84 | -$84 |
| % Margin | – | -11,203.1% | -1,089.5% | – |
| Net Income | -$74 | -$70 | -$77 | -$76 |
| % Margin | – | -10,395.1% | -1,003.6% | – |
| EPS Diluted | -0.43 | -0.41 | -0.46 | -0.45 |
| % Growth | -4.9% | 10.9% | -2.2% | – |
| Operating Cash Flow | -$62 | -$55 | -$73 | -$58 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$62 | -$55 | -$74 | -$58 |